Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014508 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00014508: Completed Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
NCT00014508 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00014508, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells are rejected by the body's tissues. Peripheral stem cell transplantation with the person's own stem cells followed by donor peripheral stem cell transplantation may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy with autologous peripheral stem cell transplantation and donor peripheral stem cell transplantation in treating patients who have multiple myeloma.
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- DRUG melphalan
- DRUG cyclosporine
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-11-19 |
| Est. Completion | 2011-05-27 |
| Phase | Phase 2 |
What the finished NCT00014508 record still lists
NCT00014508 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00014508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00014508 about?
NCT00014508 is a clinical study titled "Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells are rejected by the body's tissues. ...
What is the current status of trial NCT00014508?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-11-19. Estimated completion is 2011-05-27.
What interventions are being tested in trial NCT00014508?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), melphalan (DRUG), cyclosporine (DRUG), sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00014508?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI